Androgen Receptor- and PIAS1-regulated Gene Programs in Molecular Apocrine Breast Cancer Cells
Overview
Endocrinology
Molecular Biology
Authors
Affiliations
We have analyzed androgen receptor (AR) chromatin binding sites (ARBs) and androgen-regulated transcriptome in estrogen receptor negative molecular apocrine breast cancer cells. These analyses revealed that 42% of ARBs and 39% androgen-regulated transcripts in MDA-MB453 cells have counterparts in VCaP prostate cancer cells. Pathway analyses showed a similar enrichment of molecular and cellular functions among AR targets in both breast and prostate cancer cells, with cellular growth and proliferation being among the most enriched functions. Silencing of the coregulator SUMO ligase PIAS1 in MDA-MB453 cells influenced AR function in a target-selective fashion. An anti-apoptotic effect of the silencing suggests involvement of the PIAS1 in the regulation of cell death and survival pathways. In sum, apocrine breast cancer and prostate cancer cells share a core AR cistrome and target gene signature linked to cancer cell growth, and PIAS1 plays a similar coregulatory role for AR in both cancer cell types.
Zhong L, Ma S, Wang D, Zhang M, Tian Y, He J Genes (Basel). 2023; 14(6).
PMID: 37372369 PMC: 10298475. DOI: 10.3390/genes14061189.
Kneppers J, Severson T, Siefert J, Schol P, Joosten S, Pak Lok Yu I Nat Commun. 2022; 13(1):7367.
PMID: 36450752 PMC: 9712620. DOI: 10.1038/s41467-022-35135-2.
Genome-wide crosstalk between steroid receptors in breast and prostate cancers.
Paakinaho V, Palvimo J Endocr Relat Cancer. 2021; 28(9):R231-R250.
PMID: 34137734 PMC: 8345902. DOI: 10.1530/ERC-21-0038.
Naderi A Oncotarget. 2017; 8(34):57907-57933.
PMID: 28915724 PMC: 5593696. DOI: 10.18632/oncotarget.17826.
Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer.
Chanda A, Chan A, Deng L, Kornaga E, Enwere E, Morris D PLoS One. 2017; 12(5):e0177639.
PMID: 28493978 PMC: 5426774. DOI: 10.1371/journal.pone.0177639.